Related Experiment Videos
The Mitroflow pericardial valve: clinical performance to 10 years
J P Mazzucotelli1, P C Bertrand, D Y Loisance
1Department of Surgical Research, Henri Mondor Hospital, Creteil, France.
The Journal of Heart Valve Disease
|July 1, 1995
Summary
This study evaluated the long-term outcomes of Mitroflow pericardial bioprostheses in 366 patients undergoing valve replacement surgery. Results show moderate survival and significant structural valve deterioration at 10 years, particularly in younger patients.
Area of Science:
- Cardiology
- Cardiac Surgery
- Biomaterials Science
Background:
- Mitroflow pericardial bioprostheses were implanted in 366 patients between 1983 and 1992.
- The study included isolated aortic valve replacements (AVR), mitral valve replacements (MVR), and double valve replacements (DVR).
Purpose of the Study:
- To assess the long-term survival and durability of Mitroflow pericardial bioprostheses.
- To evaluate freedom from structural valve deterioration (SVD) and reoperation rates.
Main Methods:
- Retrospective analysis of 407 Mitroflow bioprostheses implanted from 1983-1992.
- Follow-up data collected over a mean of 6 years (1791 patient-years).
Main Results:
- Overall 10-year survival was 56.2%.
- Freedom from SVD at 10 years was 36.7% for all valves, with no significant difference between AVR and MVR.
- Freedom from reoperation at 10 years was 28.4% for all valves.
Conclusions:
- Mitroflow bioprostheses demonstrate moderate long-term survival but significant structural valve deterioration and reoperation rates at 10 years.
- Older patients (>70 years) showed better SVD-free survival.
- Pathologic findings included cuspal tears and structural tissue changes.